Publications by authors named "Yameng Hao"
Pleural mesothelioma is a fatal disease with limited treatment options. Recently, pleural mesothelioma management has improved with the development of immune checkpoint inhibitors (ICI). In first-line therapy, dual PD-1 and CTLA-4 blockade enhances tumor control and patient survival compared with chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied a new compound (called MMC) that could help treat a deadly cancer called malignant pleural mesothelioma by changing the gut microbiome.
- In their experiments, they found that mice that received MMC had slower tumor growth and lived longer than those that didn't get the treatment.
- The study showed that the MMC treatment increased certain immune cells in the tumors and changed the gut bacteria, suggesting it might be a good option to help cancer patients along with other treatments.
Objectives: Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Approaches to enhance patient immunity against MPM have been tested but shown variable results. Previously, we have demonstrated interesting vascular modulating properties of low-dose photodynamic therapy (L-PDT) on MPM.
View Article and Find Full Text PDFAtherosclerosis is a chronic inflammatory response that increases the risk of cardiovascular diseases. An in-depth study of the pathogenesis of atherosclerosis is critical for the treatment of atherosclerotic cardiovascular disease. The development of atherosclerosis involves many cells, such as endothelial cells, vascular smooth muscle cells, macrophages, and others.
View Article and Find Full Text PDF(E)-3,4-dihydroxystyryl alkyl sulfones, as new analogues of neurodegenerative agents, were designed and synthesized. The biological results demonstrated that most of the target compounds preserved antioxidant and anti-inflammatory potency in scavenging reactive free radicals, protecting neuronal cells against neurotoxins such as HO, 6-hydroxydopamine and inhibiting lipopolysaccharide (LPS)-induced over-production of NO. Among these compounds, 6.
View Article and Find Full Text PDFArticle Synopsis
- Tissue factor pathway inhibitor (TFPI) plays a crucial role in reducing atherosclerosis by regulating the coagulation pathway linked to tissue factor (TF).
- The review highlights recent insights into how TFPI inhibits endothelial cell activation, vascular smooth muscle cell behavior, inflammatory recruitment, and extracellular matrix changes associated with atherosclerosis.
- Additionally, the article discusses the significance of TFPI levels and genetic variations in relation to clinical atherogenesis, aiming to provide new perspectives for research on atherothrombosis.
Fibroblast growth factor (FGF)‑21, a member of the family of FGFs, exhibits protective effects against myocardial ischemia and ischemia/reperfusion injury; it is also an enhancer of autophagy. However, the mechanisms underlying the protective role of FGF‑21 against cardiomyocyte hypoxia/reoxygenation (H/R) injury remain unclear. The present study aimed to investigate the effect of FGF‑21 on H9c2 cardiomyocyte injury induced by H/R and the mechanism associated with changes in autophagy.
View Article and Find Full Text PDFArticle Synopsis
- * Endothelial to mesenchymal transition (EndMT) represents a change in endothelial cells that can lead to conditions like vascular remodeling and myocardial fibrosis.
- * Understanding the signaling pathways involved in EndMT could lead to new treatments for atherosclerosis and related diseases.